Skip to main content
. 2021 Sep 28;2(12):1998–2009. doi: 10.34067/KID.0005062021

Figure 1.

Figure 1.

AlloMap Kidney classifier differentiates quiescence from rejection in the primary independent validation set. (A) Box-and-whisker plots show that biopsy specimen–defined rejections (n=18) were significantly different from quiescence (n=98). (B) No difference among quiescence subgroups, including nonrejection (NR), protocol NR (pNR), and healthy stable (HS) subgroups; all three were significantly lower than T cell–mediated rejection (TCMR) and antibody mediated rejection (ABMR). HS, n=22; pNR, n=29; NR, n=47; TCMR, n=7; ABMR, n=10; mixed rejection, n=1. (C) TCMR results stratified by grade suggest a trend for AlloMap Kidney and TCMR grade. (D) Receiver operating characteristic plot for the primary validation set with rejection compared with quiescence (red line) or NR (blue line). Unpaired t test.